The company is poised to take advantage of clear overarching macro revenue drivers.

The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?

Turmoil with the board culuminates in the departure of the CEO.

A sound business model but the shares are expensive.

Road to profitability is in sight as management continues to take the right steps.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

Solid device sales with shares moderately undervalued.

We raise our fair value on this high-flyer.

Shares drop 17% after guidance is revised but we still see value.

The shares are trading at a 47% premium to our fair value.